Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 25, 2023, Cue Biopharma (Nasdaq: CUE) announced the appointment of Dr. Pamela D. Garzone to its board of directors. Dr. Garzone brings over 25 years of experience in the healthcare and pharmaceutical sectors, particularly in drug development and regulatory leadership. Her expertise spans various therapeutic areas, including immuno-oncology, which aligns with Cue Biopharma’s focus on developing innovative biologics aimed at engaging disease-specific T cells within patients. Cue Biopharma aims to enhance treatment options for cancer and autoimmune diseases using its proprietary Immuno-STAT™ platform. The CEO, Daniel Passeri, expressed confidence that Dr. Garzone’s experience will provide strategic insights as the company advances its clinical and preclinical pipeline.
Cue Biopharma (CUE) has announced the appointment of Patrick Verheyen to its Board of Directors, bringing over 35 years of experience from Janssen Pharmaceutical. Verheyen's expertise in business development and M&A is expected to enhance Cue's corporate growth and current drug candidates, CUE-101 and CUE-102. Daniel Passeri, CEO of Cue Biopharma, expressed enthusiasm for Verheyen's insights, aiming to broaden the company’s strategic initiatives in immunotherapy for autoimmune diseases and cancer. Verheyen's past achievements include leading significant acquisitions at Janssen, which expanded its pipeline and established a global innovation presence.
On March 21, 2023, Cue Biopharma reported significant advancements in its clinical initiatives and financial results for 2022. The FDA accepted its IND application for CUE-102 targeting WT1-expressing cancers and started a Phase 1 trial. CUE-101 received Fast Track Designation for HPV+ head and neck cancers. The 2022 collaboration revenue dipped to $1.2 million from $14.9 million in 2021, while net losses increased to $53 million, affected by reduced research funding and expenses. However, cash reserves rose to $76.3 million, expected to support operations until late 2024. The company aims to present updated data on its oncology programs in upcoming conferences.
Cue Biopharma (Nasdaq: CUE) will host a conference call and webcast on March 21, 2023, at 4:30 p.m. EDT to discuss business and clinical updates. The session will detail ongoing trials of CUE-101, an IL-2-based biologic targeting HPV+ head and neck cancer, and CUE-102 for WT1-expressing cancers. The company also plans to discuss its partnership with Ono Pharmaceutical aimed at advancing CUE-401 for autoimmune diseases. Investors can join via phone or webcast, with registration available on the company's website.
BOSTON, March 1, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in two healthcare investor conferences this March: the Cowen 43rd Annual Health Care Conference (March 6-8) and the Oppenheimer 33rd Annual Healthcare Conference (March 13-15). The presentations will showcase advancements from the IL-2-based CUE-100 series of biologics, including details on ongoing Phase 1 trials for its drug candidate, CUE-101, targeting HPV+ cancers, and CUE-102 for Wilms’ Tumor 1 positive cancers. The company also announced a partnership with Ono Pharmaceutical to advance CUE-401 for autoimmune diseases.